Drug reference

Emtricitabine with tenofovir alafenamide

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 710

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

HIV infection in combination with other antiretroviral drugs (specialist use only) ▶BY MOUTH ▶Adult: 200/10–200/25 mg once daily, dose is dependent on drug regimen—consult product literature DOSE EQUIVALENCE AND CONVERSION ▶Dose expressed as x/y mg emtricitabine/tenofovir alafenamide.

PDF page 710

National Funding Access Decisions

Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (August 2016) that emtricitabine with tenofovir alafenamide (Descovy ®) is accepted for use within NHS Scotland for the treatment of human immunodeﬁciency virus type 1 in combination with other antiretroviral agents. All Wales Medicines Strategy Group (AWMSG) decisions The All Wales Medicines Strategy Group has advised (September 2016) that emtricitabine with tenofovir alafenamide (Descovy ®) is recommended as an option for use within NHS Wales for the treatment of human immunodeﬁciency virus type 1 in combination with other antiretroviral agents.

PDF page 710

Safety

Interactions

→Appendix 1: tenofovir alafenamide

PDF page 710

Side Effects

▶Common or very common Abnormal dreams. diarrhoea. dizziness. fatigue. ﬂatulence. gastrointestinal discomfort . headache. nausea. skin reactions. vomiting ▶Uncommon Anaemia. arthralgia ▶Frequency not known Angioedema. osteonecrosis

PDF page 710

Hepatic Impairment

Manufacturer advises caution (increased risk of hepatic side-effects).

PDF page 710

Renal Impairment

Manufacturer advises avoid if creatinine clearance less than 30 mL/minute—limited information available.

PDF page 710

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Descovy (Gilead Sciences International Ltd) A Tenofovir alafenamide (as Tenofovir alafenamide fumarate) 25 mg, Emtricitabine 200 mg Descovy 200mg/25mg tablets | 30 tablet P £355.73 Tenofovir alafenamide (as Tenofovir alafenamide fumarate) 10 mg, Emtricitabine 200 mg Descovy 200mg/10mg tablets | 30 tablet P £355.73

PDF page 710

Clinical care

Patient And Carer Advice

Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.

PDF page 710

Dose text by age group

Adult

200/10–200/25 mg once daily, dose is dependent

First-line fragment. Read the complete Indications and Dose section above.

PDF page 710

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Emtricitabine with tenofovir alafenamide

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 710

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 710

National Funding Access Decisions

PDF page 710

Safety

Interactions

→Appendix 1: tenofovir alafenamide

PDF page 710

Side Effects

PDF page 710

Hepatic Impairment

Manufacturer advises caution (increased risk of hepatic side-effects).

PDF page 710

Renal Impairment

Manufacturer advises avoid if creatinine clearance less than 30 mL/minute—limited information available.

PDF page 710

Dose and formulations

Medicinal Forms

PDF page 710

Clinical care

Patient And Carer Advice

Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.

PDF page 710

Dose text by age group

Adult

200/10–200/25 mg once daily, dose is dependent

First-line fragment. Read the complete Indications and Dose section above.

PDF page 710

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.